Jamaica focused on attracting more sustainable and innovative investments in 2022
As Jamaica pursues its Vision 2030 development plan which will transform the island’s economy, the country’s government continues to develop and seek innovative investments that can accelerate economic and social growth.
These investment projects will not only provide economic rewards, but will also be sustainable, create new avenues for development in communities, towns, and cities, and will lead to significant improvement in Jamaica’s overall business environment.
Jamaica’s Minister of Industry, Investment and Commerce, Senator the Honourable Aubyn Hill, noted that the government has expended significant resources to foster an enabling environment for economic growth. “Our long term goal is for investment products and partnerships that are sustainable, that will energize our economy and drive positive change at all levels of society,” the Minister underscored.
“We consider innovative investments to be all about sustainability, transformation and expansion,” explained Norman Naar, Vice President of Sales and Promotions at Jamaica’s investment and export promotions agency, JAMPRO. “These investments will help to protect our environment, meet the challenge of climate change, and create employment opportunities across the society. They will make Jamaica more competitive and strengthen connections between investors and suppliers.”
Ultimately, the goal is to encourage and facilitate the development of products and services that will enhance the lives of the island’s population. These products and services will also use technology to advance sectors like agriculture, manufacturing, tourism, and others.
Innovative investment projects already underway – with more to come
There are a number of innovative and sustainable investment projects already underway within the Jamaican economy.
In the energy sector, there are three significant solar and wind energy projects generating 115MW kWh in renewable energy; approximately 14 percent of energy generation. Renewable energy is a significant part of Jamaica’s Integrated Resource Plan, which aims to achieve 30 percent of electricity generation from renewables by 2030.
These projects include the 20-megawatt (MW) Content Solar Ltd. solar energy electricity generation plant owned by WRB Energy Company; the Wigton windfarm with a 20.7 MW plant and an 18 MW extension facility, the largest wind energy facility in the English-speaking Caribbean; and Jamaica’s largest photovoltaic power plant, the 51 MWp (megawatts-peak) Paradise Park solar farm, one of the cheapest producers of energy in the country.
In manufacturing, the government has highlighted the island’s “clean beauty” sector as an area of focus, where investors would partner with local manufacturers of beauty products that use ethically sourced ingredients like local castor oil. Helping these local companies increase production and find additional markets will increase employment in the communities from which they source their workers and boost the manufacturing industry.
Another area of focus in manufacturing is the transformation of plants like bamboo to create raw materials and value-added products. The Bamboo Bioproducts (BBP) project, for example, will be the world’s first fully integrated bamboo pulp mill, using a sustainable agro-ecological-industrial model. Locally grown bamboo acquired from company-owned lands and managed farms across the island will be used to manufacture bamboo pulp, which will be exported to global markets.
In tourism, there are opportunities to create wellness and eco-tourism projects that will protect Jamaica’s environment, while building on the country’s strong brand as a destination for visitors.
With regards to agriculture, Naar revealed, “We are seeking innovative investments in agribusiness that can improve the sector’s resilience, profitability, and output. In the leveraging of technology in agriculture, we look to reduce risk of theft, improve consistency and significantly increase yield or scale of production. Therefore, we have a major drive to increase the use of agriculture tech or Agtech as it is also known.”
This includes the creation of projects that have Agtech elements like controlled environment agriculture, automation of commercial greenhouses, and precision farming. Climate smart agriculture and climate-resilient crops are also needed.
Investment in medicinal plants and the cannabis industry will provide the opportunity to boost medical research and will lead to the development of pharmaceuticals and nutraceuticals.
Priority Investment Project initiative will facilitate more investments
To increase the level of these innovative investments that are sustainable, and to create economic benefits and local business and community involvement, the government has launched the Priority Investment Project Initiative as part of Jamaica’s National Investment Policy.
The initiative prioritizes projects that will have high performance in areas like economic impact, innovation, linkages, investment in internationally competitive industries, and developmental impact on the local economy. Once a project meets the required standards and is approved by Jamaica’s Cabinet, the investors will receive non-fiscal benefits to assist in overcoming challenges they may face with the venture.
Regarding the initiative, Minister Hill said, “We are serious about fostering investments that bring innovation to the Jamaican economy, and that includes working with investors as partners in achieving their goals. This priority investment initiative will help us to give these projects even more support; at the same time, it helps to ensure that we meet our Vision 2030 objectives through projects that will provide a major boost to our economy and society.”
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce. For more information on JAMPRO, please visit https://dobusinessjamaica.com/.
Follow us on:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005258/en/
Contact information
Tamica Parchment
Marketing Communications
JAMPRO
(876) -978-7755
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 09:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the highly respected JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 years, from 2004 through 2024. Debiopharm is now transitioning its historic award into the IDEAL Japan initiative aiming to accelerate preclinical scientific research that could give rise to new treatments for cancer patients. “Our vision is to collaborate to find a cure for cancer,”explained Thierry Mauvernay, President of Debiopharm. “We believe that our ongoing Swiss-Japanese connection needs to evolve and catalyze the trans
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 08:00:00 EET | Press release
Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/ Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio. Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings toget
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 05:35:00 EET | Press release
Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through its partners by the end of October 2025, marking a threefold increase compared to the same period in 2024, with MSMEs among the key segments driving this growth. International Finance Corporation estimates a US$8 trillion financing gap for MSMEs in emerging markets and developing economies. With global platforms, from e-commerce to food delivery, entering emerging markets and local platforms in these markets continue to scale, many are looking to offer tailored credit services to better support MSMEs operating on their ecosystems. Doin
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 05:00:00 EET | Press release
Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in real-time global treasury management. It has already supported a successful H
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo ™ 300mg18.11.2025 04:51:00 EET | Press release
The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These improvements may contribute to an enhanced treatment journey for patients by helping reduce the disease burden they face throughout their care. Given its distinctive product profile, Omlyclo™ 300mg has the potential to become an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
